Compare · STVN vs SYK
STVN vs SYK
Side-by-side comparison of Stevanato Group S.p.A. (STVN) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STVN and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.60B, about 21.2x STVN ($5.96B).
- Over the past year, STVN is down 23.4% and SYK is down 17.5% - SYK leads by 5.9 points.
- SYK has been more active in the news (2 items in the past 4 weeks vs 1 for STVN).
- SYK has more recent analyst coverage (25 ratings vs 22 for STVN).
- Company
- Stevanato Group S.p.A.
- Stryker Corporation
- Price
- $19.76+1.78%
- $330.37+3.52%
- Market cap
- $5.96B
- $126.60B
- 1M return
- +14.75%
- +5.30%
- 1Y return
- -23.40%
- -17.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 2
- Recent ratings
- 22
- 25
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest STVN
- Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
- Director Balachandran Madhavan was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 5% to 69,458 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Dal Lago Marco was granted 2,356 units of Ordinary Shares and converted options into 7,997 units of Ordinary Shares, increasing direct ownership by 14% to 85,353 units (SEC Form 4)
- Director Lin Sue-Jean was granted 4,975 units of Ordinary Shares, increasing direct ownership by 249% to 6,975 units (SEC Form 4)
- Director Morel Donald E Jr was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 10% to 37,424 units (SEC Form 4) (tax withholding)
- Director Santel Luciano was granted 4,975 units of Ordinary Shares, increasing direct ownership by 278% to 6,762 units (SEC Form 4)
- Director Magistretti Elisabetta was granted 4,975 units of Ordinary Shares (SEC Form 4)
- Officer Stocchi Mauro was granted 2,101 units of Ordinary Shares and converted options into 6,586 units of Ordinary Shares, increasing direct ownership by 2% to 413,629 units (SEC Form 4)
- Director Flynn Karen was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 153% to 5,757 units (SEC Form 4) (tax withholding)
- Director Federici William J was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 15% to 26,991 units (SEC Form 4) to satisfy withholding obligation
Latest SYK
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)